Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Truxima® (rituximab-abbs) – New biosimilar approval
November 28, 2018 - The FDA announced the approval of Teva/Celltrion’s Truxima (rituximab-abbs), biosimilar to Genentech/Biogen’s Rituxan® (rituximab).
